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Summary
Objective: To evaluate the inﬂuence of cyclodextrin polysulphate (CDPS) on the extracellular matrix (ECM) metabolism of human articular
cartilage chondrocytes.
Methods: Isolated chondrocytes from femoral condyle cartilage of human knee joints were cultured in gelled alginate to maintain their
differentiated phenotype. During 1 week of culture, the cells were exposed to different concentrations of CDPS. Synthesis of aggrecans was
investigated in these cultures after using Na2
35SO4 as a radioactive precursor during the last 24 h of culture. The artiﬁcial matrix was then
solubilised with Na-citrate and newly synthesised aggrecan aggregates, accumulated during culture, were liberated and assayed. The isolated
chondrocytes were labelled with antibodies against aggrecan and type II collagen to analyse the ECM molecules in the cell-associated matrix
(CAM). Plasma membrane levels of receptors for insulin-like growth factor-1 (IGF-1RI) and for interleukin-1 (IL-1RI and IL-1RII), as well as
levels of IGF-1, IL-1a and -b were determined after the cells had been permeabilized and stained with the appropriate antibodies. The release
of IL-6 in the culture media was used as a variable reﬂecting auto/paracrine IL-1 activity of the cells in different experimental conditions.
Results: CDPS signiﬁcantly increased total 35S-incorporation rates in ECM aggrecan. When compared with controls, CDPS-treated
chondrocytes expressed signiﬁcantly higher CAM aggrecan and type II collagen levels. As plasma membrane-bound IGFR1 and intracellular
IGF-1 levels remained unchanged, this increase in accumulated CAM compounds may have resulted from suppressed catabolic activities by
the chondrocytes in culture. CDPS-treated cells expressed signiﬁcantly lower amounts of intracellular IL-1a and -b levels. Plasma membrane-
bound IL-1RI and decoy IL-1RII remained unchanged. b-cyclodextrin-treated chondrocytes released signiﬁcantly less IL-6 in the supernatant
culture media.
Conclusion: CDPS is a novel polysulfated polysaccharide showing cartilage structure modifying effects in vitro as it improves the synthesis of
aggrecan and the accumulation of CAM macromolecules. This effect probably resulted in part from the downregulation of IL-1.
ª 2005 Published by Elsevier Ltd on behalf of OsteoArthritis Research Society International.
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Sulphated polysaccharides have been licensed for the use
in different pathophysiological conditions, e.g., to modulate
plasma anticoagulant and ﬁbrinolytic activities, to exert
hypolipaemic effects, to inhibit retroviral multiplication.
Interestingly, most of these distinct effects are shared by
different polysulphated polysaccharides.
Where degenerative joint diseases are concerned, the
most interesting biological activities of these sulphated
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important compounds of the extracellular matrix (ECM) of
connective tissues. The ﬁrst reports already dated from the
early 1970s1e4 but extended reviews on the potential use of
these polysaccharides have appeared more recently5,6.
Amongst other glycosaminoglycans, chondroitin sulphate
was shown to increase aggrecan synthesis by articular
cartilage cells7 and both chondroitin sulphate and chon-
droitin polysulphate (CPS) increased hyaluronan synthesis
by synovial lining cells in vitro8 and in vivo9,10. Interestingly,
hyaluronan molecular weight signiﬁcantly increased when
synovial cells were treated with CPS and other sulphated
polysaccharides9e11. Similarly, human articular chondro-
cytes in monolayer culture responded with an increased
synthesis of highly polymerised hyaluronan when CPS was
supplemented to the culture medium12. Under the same
conditions these articular cartilage cells increased their
production of aggrecans in the aggregate form13. Electron
microscopic studies conﬁrmed the immobilisation of higher
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synthesised by differentiated human cartilage cells exposed
to CPS and other sulphated polysaccharides such as
xylosan polysulphate13.
Considering their capability of increasing synthesis rates
and improving the immobilisation of physiologically impor-
tant ECM molecules, some of these sulphated polysac-
charides have been considered to be important
therapeutical tools in osteoarthritis (OA), where declining
aggrecan synthesis rates and the decreased capability of
assembling large molecular size aggregates illustrate the
progressive failure of the repair function of articular cartilage
cells. A damaged articular cartilage can affect the normal
function of the joint and this ultimately results in clinical
symptoms in a proportion of the patients14. Structure/
disease modifying OA drugs (DMOADs) are expected to
prevent structural damage in normal joints at risk for
development of OA, or to retard the progression of
structural damage in joints already affected by OA15.
A major ﬂaw when these substances are introduced for
pharmacological use in humans is their poor chemical
deﬁnition. The exact molecular weight is varying. The
degree and type of sulphation is different on each of the
individual molecules. One class of biologically occurring
polysaccharides with well-deﬁned molecular structure and
weight are the cyclodextrins. a-, b- and g-cyclodextrins are
cyclic polysaccharides containing 6, 7 and 8 glucopyra-
nose units, respectively, linked through a1-4 glycosidic
bonds. Classical sulphation procedures result in the
sulphation of the three free hydroxyl groups of the
glucopyranoses.
a-, b- and g-cyclodextrins have been fully sulphated and
the inﬂuence of these cyclodextrin polysulphates (CDPSs)
on the ECM metabolism of human articular cartilage
chondrocytes has been evaluated. The incorporation of
radiosulphate in proteoglycan was used as a variable to
assess which concentrations of the cyclodextrins would
result in an effect on chondrocyte metabolism. Once the
optimal working concentrations were deﬁned, the effects on
factors known to affect the homeostasis of the ECM by
chondrocytes from intact articular cartilage were assessed
in more detail.Materials and methods
PREPARATION OF SULPHATED a-, b-, AND c-CYCLODEXTRINS
Commercially available a-, b-, and g-cyclodextrins
(Sigma Chemical Company, St. Louis, USA) were sulph-
ated according to the procedure described by Astrup
et al.16. Brieﬂy, drop-by-drop, one volume of chlorosul-
phonic acid was added to 6.6 volumes of ice-cold pyridine.
Approximately, 300 mg of the polysaccharides was added
to 5 ml of the chlorosulphonic/pyridine mixture. The solution
was then kept at 100(C for 5 h. After cooling, 25 ml of
distilled water was added. One hundred milliliters of 10%
(w/v) Na-acetate in methanol was then added to this
solution to precipitate the polysaccharide polysulphuric
acids. The precipitate was washed two times in methanol
and dissolved in an appropriate amount of distilled water
before being applied to a Sephadex G10 gel permeation
chromatography column to elute the remaining chlorosul-
phonic acid, pyridine and buffer salts. The void volume
fractions containing the polysaccharides were lyophilised.
The cyclodextrin polysulphates were recovered as a dry
white powder. Electrophoresis on cellulose acetate in a
LiCl/HCl (0.01/0.06 N) buffer pH 3.5, at 1 mA/cm kept for
20 min was done to evaluate the degree of sulphation of the
cyclodextrins and showed the polysulphated cyclodextrins
migrating as homogeneous bands and with the same
velocity as the CPS or xylosan polysulphate standards
(Fig. 1). Mass Spectrometry was done in the Institut de
Recherche SERVIER Laboratories (Orleans, France; Dr F
Lefoulon) and conﬁrmed complete sulphating of all cyclo-
dextrin glucopyranoses. Considering initial molecular
weights of 973, 1135 and 1297 Da for the unsulphated a-,
b-, and g-cyclodextrins, respectively, on sulphation of the
three free hydroxyl groups of the glucopyranoses their
molecular weights increased to 2413, 2815 and 3217. The
CDPSs were used as such in our experimental in vitro
models.
ISOLATION OF ARTICULAR CHONDROCYTES
Human articular chondrocytes were isolated as described
elsewhere17. Brieﬂy, human articular cartilage was obtainedO
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Fig. 1. A: Synthesis of CDPSs e schematic representation. B: Cellulose acetate electrophoresis of the sulphated polysaccharides.C: Positive
pool;/: start; lane 1: hyaluronan, chondroitin sulphate; lane 2: chondroitin sulphate; lane 3; CPS; lane 4: a-CDPS; lane 5: b-CDPS; lane 6:
g-CDPS; lane 7: xylosan polysulphate.
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within 24 h post-mortem. All donors had died after a short
illness. None of them had received corticosteroids or
cytostatic drugs. Both visually intact and ﬁbrillated OA
femoral condyle cartilage samples were harvested sepa-
rately and prepared for culture. The cartilage samples were
diced into small fragments and the chondrocytes were
isolated by sequential enzymatic digestion (hyaluronidase,
pronase and collagenase) of the ECM as described in
detail22. Isolated cells were then centrifuged for 10 min at
1500 rpm, washed three times in dulbecco’s modiﬁed
eagle’s medium (DMEM) with 10% (v/v) fetal calf serum
(FCS), tested for viability (Trypan Blue exclusion test) and
counted. More than 95% of the cells were usually viable
after isolation.
CULTURES IN ALGINATE GEL
Chondrocyte cultures in alginate beads were prepared as
described elsewhere18, with some modiﬁcations. Chondro-
cytes suspended in one volume of double-concentrated
Hank’s Balanced Salts Solution without calcium and
magnesium (HBSS; Gibco) were carefully mixed with an
equal volume of 2% (w/v) alginate (low-viscosity alginate
from Macrocystis pyrifera; Sigma) in HBSS, autoclaved for
15 min. The ﬁnal cell concentration was 5! 106 chondro-
cytes/ml in 1% alginate. The chondrocyte/alginate suspen-
sion was then slowly dripped through a 23-gauge needle into
a 102 mMcalcium chloride solution. The beadswere allowed
to polymerise for 10 min at room temperature. The calcium
chloride was then removed, the beads were washed three
times with 0.15 M sodium chloride and ﬁnally maintained in
a 6-well plate with 1! 106 cells per culture (each well
containing 20 alginate beads; G50,000 chondrocytes per
bead) in 4 ml of DMEM with 10% FCS and 50 mg ascorbate/
ml in an incubator at 37(C under 5% CO2. The nutrient
medium was replaced twice weekly for 7 days. Recently, we
described that ECM metabolism by chondrocytes reached
steady state after 1 week in this alginate culture system19.
INCORPORATION OF 35SULPHATE TO MEASURE NEWLY
SYNTHESISED AGGRECANS
Incorporation of 35Sulphate to measure newly synthes-
ised aggrecans by chondrocytes cultured in alginate was
investigated using Na2
35SO4 as a radioactive precursor. As
the optimal working concentrations of the oversulphated
cyclodextrins were not known, chondrocytes obtained from
six donors were used to test different concentrations
(0.5e10.0 mg/ml) of the oversulphated cyclodextrins. The
cyclodextrins were supplemented to the nutrient media
during the whole culture period. After a 1-week culture
period in alginate, 10 mCi/ml of the label was included in the
incubation medium over 24 h. During this period, newly
synthesised 35S-aggrecans partly accumulated in the
artiﬁcial matrix. The alginate was then solubilised with
3 ml of 55 mM tri-sodium citrate dihydrate pH 6.8, 0.15 M
NaCl at 25(C for 10 min and suspension was centrifuged.
35S-labelled macromolecules from the resulting supernatant
were pooled with 35S-material that had escaped to the
nutrient medium, and stored for further chromatography.
Aliquots of pools of combined media and alginate digests
were desalted through Sephadex G25 (Pharmacia) chro-
matography gels in 0.067 M phosphate (K2HPO4/Na2HPO4)
pH 6.8, containing 0.01 M Na2SO4, to separate
35S-labelled
aggrecans (void volume) from free 35Sulphate (retarded
fraction). The eluted fractions were counted for radioactivity.The radioactivity in the void volume is related to the total
incorporation of 35Sulphate in newly synthesised aggrecans
by the respective cultures. Considering the amount of
pooled culture medium that ultimately was analysed after
chromatography, the speciﬁc activity of the incubation
medium (mCi 35SO4 per mM cold SO4), the decay of
35Sulphate, the labelling period in hours and the numbers of
cells per culture, we were able to express sulphate
incorporation as picograms of SO4 incorporated per
1! 106 chondrocytes/h20.
IL-6 RELEASE BY CHONDROCYTES
Chondrocytes obtained from both visually intact and
ﬁbrillated cartilage of a 69-year-old female donor who
presented a focal OA lesion, were kept in culture
separately, and exposed to 0.0 and 5.0 mg/ml of b-CDPS
for 1 week. Additionally, normal chondrocyte cultures with
and without b-cyclodextrin were exposed to 100 pg/ml of
tumor necrosis factor alpha(TNFa) (R&D systems, Abing-
don, UK) during the last 48 h in culture. Culture media were
then assayed for interleukin-6 (IL-6) by conventional
enzyme linked immunosorbent assay (ELISA).
FLOW CYTOMETRIC ASSAY OF CELL-ASSOCIATED ECM
MOLECULES AND OF INTRACELLULAR CYTOKINE
AND GROWTH FACTOR LEVELS
Chondrocytes obtained from three additional donors were
used to test the effects of the cyclodextrins on the activity of
autocrine cytokine and growth factor pathways and on the
presence of cell-associated matrix (CAM) molecules. The
chondrocytes were cultured in alginate and in the presence
of 0.0, 2.5 and 5.0 mg/ml of CDPS for a period of 7 days
after which time culture medium was removed and alginate
beads processed as described above. The resulting
suspension was centrifuged at 1500 rpm for 10 min to
separate cells with their CAM19,21 from the constituents of
the interterritorial matrix. The pellet with the chondrocytes
was recovered to assess the CAM macromolecule con-
tents, the plasma membrane-bound receptors and the
intracellular levels of cytokines and growth factors. Insulin-
like growth factor receptor-1 (IGFR1), IL-1RI and -II on the
cell membrane and aggrecan, type II collagen and
ﬁbronectin in the CAM were tested directly after incubation
with the appropriate antibodies for 30 min in the dark at
4(C. Twenty microliters of 50 mg/ml ﬂuorescein isothiocya-
nate (FITC)-labelled antibodies were used to react with
2! 105 cells resuspended in 100 ml phosphate buffered
saline (PBS). In order to evaluate the expression of IGF-1,
IL-1a and -b inside the cells, cultures were incubated with
monensin (GolgiStop, 4 ml/6 ml medium) for 5 h to block
the protein transport from Golgi apparatus. Following this,
chondrocytes were permeabilized using Cytoﬁx/Cytoperm
Plus Kit (PharMingen, San Diego, CA, USA) according to
the manufacturer’s instruction. The cells were treated with
Cytoﬁx/Cytoperm solution for 20 min. After a wash in 1!
Perm/Wash solution, the procedure was followed by the
incubation with monoclonal antibodies (mAb).
ANTIBODIES USED FOR FLOW CYTOMETRY
Mouse anti-human mAb (subclass: IgG1) against IGFR1,
IL-1RI, IL-1RII, IL-1b and the mouse IgG1 negative control
were purchased from R&D systems (Abingdon, UK; IGFR1:
clone 33255.111; IL-1RI: clone 35730.111; IL-1RII: clone
34141.11; IL-1b: clone 8516.311). Mouse anti-human IGF-1,
IL-1a and anti-human chondrocyte-speciﬁc aggrecan
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Belgium; IGF-1: clone AHG0014; IL-1a: clone 624B3F2;
aggrecan: clone 4D11-2A9). Polyclonal anti-ﬁbronectin
rabbit IgG were from Chemicon International (Harrow,
UK). Mouse anti-human type II collagen mAb (clone II-
4C11, ICN Biochemicals, Ohio, USA) was chosen to detect
type II collagen. All the antibodies (except aggrecan and
type II collagen) were conjugated with FITC (Isomer I,
SigmaeAldrich, Belgium) as previously described22. The
anti-aggrecan and type II collagen mAbs were conjugated
with phycoerythrin (PE, SigmaeAldrich)23. The conjugated
mAbs were used in a direct immunoﬂuorescent staining
protocol for ﬂow cytometry. Appropriate FITC- or PE-
labelled isotype matched mouse or rabbit IgG1 (Becton
Dickinson: clone X40) was used as a negative control.
FLOW CYTOMETRIC ANALYSIS
Stained cells were analysed on a ﬂow cytometer
(FACSort, Becton Dickinson, San Jose, CA, USA) with
CELLQuest software. From each sample, 15,000 events
were analysed. Cells were gated on forward and side scatter
to exclude debris and aggregates. Propidium iodide was
additionally used to exclude dead cells when the epitopes
outside the cells, i.e., IGFR1, IL-1RI and -II and ECM
molecules, were analysed22,24. The median ﬂuorescence
intensity (MFI) of the positive cell population, which is due to
the binding of the conjugated antibodies, was used to
quantify the presence of IGFR1, IL-1RI and -II on the plasma
membrane, of the ECM molecules in the CAM, and the
accumulation of IGF-1, IL-1a and -b inside the cells. To
differentiate the positive mAb-stained cells, the interface
channel for positivity was set at the point where less than 2%
of the control ﬂuorescence (cells exposed to FITC/PE
isotype matched IgG) was positive. MFI values of these
mAb-stained chondrocyte populations were then calculated.
For comparison between experiments the Quantum
Simply Cellular Microbead Kit (Sigma) was used to calibrate
the ﬂuorescence scale of the ﬂow cytometer. The product
contains a mixture of four uniform microbead populations,
which differ by their incremental capacities to bind mouse
IgG. The microbeads were stained and processed in
parallel with the cell samples using the same amount of
FITC-labelled antibodies and incubation time. The ﬂuores-
cence scale of the cytometer was adapted before every
experiment in order to keep identical MFIs for the four peaksof the calibration beads. The MFI of cell samples was then
analysed without changing any instrument settings.
STATISTICS
Mean 35S-incorporation rates or mean MFI values for the
different parameters in each of the donor chondrocytes
were calculated from triplicate cell cultures. As the 35S-
incorporation experiments were done on the cells obtained
from six donors, the mean 35S-incorporation values in the
untreated controls were normalised to 100 to allow
percentage changes after the exposure to different con-
centrations of CDPS to be presented. Mean MFI values in
the untreated controls were compared with these obtained
after the exposure to different concentrations of CDPS.
Paired Student’s t tests were used to test signiﬁcance and
to study the effect sizes of the changes in the chondrocyte
cultures after CDPS treatment. Signiﬁcance levels for all
tests were set at PZ 0.05.
Results
EFFECT OF DIFFERENT CONCENTRATIONS OF a-, b- AND
c-CYCLODEXTRINS ON AGGRECAN SYNTHESIS RATES
Synthesis of aggrecans was investigated using Na2
35SO4
as a radioactive precursor. The incorporation of SO4 was
expressed as picograms of SO4 incorporated in aggrecan
macromolecules per 1! 106 chondrocytes/h (Table I). As
optimal doses of use of the a-, b- and g-cyclodextrins were
not known, and information about any differential effects of
the three cyclodextrin was lacking, broader dose ranges
were used in the ﬁrst two donor cells. The chondrocytes of the
last four donors were used to explore effects of and/or
differences between the three cyclodextrin types at the
optimal concentration of 2.5e5.0 mg/ml of culture medium.
a-, b- and g-cyclodextrins, used at 0.5, 1.0 and 10.0 mg/ml
concentrations, failed to provoke consistent signiﬁcant
increases in 35S-incorporation in aggrecan in two ﬁrst donors.
At concentrations ranging between 2.5 and 5.0 mg/ml, a-,
b- and g-cyclodextrins signiﬁcantly improved aggrecan
synthesis by the chondrocytes of four other donors. Higher
concentrations of the oversulphated cyclodextrin inhibited
35S aggrecan synthesis (Table I). In a control experiment on
the cells obtained from donor F53, unsulphated cyclodextrinTable I
Effects of polysulphated cyclodextrins on the synthesis of ECM 35S-aggrecan by chondrocytes in alginate
Donor CD Control 0.5 mg of CD/ml 1.0 mg of CD/ml 2.5 mg of CD/ml 5.0 mg of CD/ml 10.0 mg of CD/ml
M19 b 8525G 450 9844G 781*1 11,350G 302*3 10,814G 227*3
F36 a 19,774G 467 19,151G 1501 21,953G 1987 21,100G 735*1 22,524G 1249*1
F36 b 19,774G 467 23,303G 90*4 23,666G 1625*2 23,043G 1216*2 19,514G 500
F36 g 19,774G 467 22,991G 3193 24,236G 2473*1 24,392G 1715*2 20,189G 392
M36 a 13,677G 368 17,793G 708*4
M36 b 13,677G 368 18,048G 610*4
M36 g 13,677G 368 15,036G 798*1
M39 a 3415G 1253 6177G 415*2 5733G 874*1
M39 b 3415G 1253 6044G 1248*2 6168G 768*1
M39 g 3415G 1253 5884G 1202*1 5902G 1065*1
M41 b 13,165G 1337 16,719G 2090*1 18,329G 3288*1
F53 b 6649G 2121 11,030G 952*2
unsulf 6649G 2121 7603G 1703
Mean valuesG 1 SD are presented; Donor: M/F-NR: male/female-age; CD: a-, b-, or g-cyclodextrin; unsulf: unsulphated CD; *NR:
signiﬁcance, levels: *1: P! 0.05; *2: P! 0.01; *3: P! 0.001; *4: P! 0.001.
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(Table I). Percentage changes in 35S-incorporation in
aggrecan induced by different concentrations of the three
cyclodextrins are given in Fig. 2.
FLOW CYTOMETRIC ANALYSIS OF THE CAM CONTENT
Following the results of the dose-ﬁnding studies, b-
cyclodextrin at 2.5 and 5.0 mg/ml concentrations was used
in ﬂow cytometry experiments on the cells of three
additional donors. When compared with controls, 2.5 mg/ml
of b-CDPS-treated chondrocytes showed a signiﬁcantly
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Fig. 2. Percentage changes in 35S-incorporation in aggrecan
induced by different concentrations of CDPSs. Dots represent
mean values of experiments in triplicate. Bars represent median
values.B: effect of a-cyclodextrins, : effect of b-cyclodextrins,C:
effect of g-cyclodextrins.increased accumulation of aggrecan, type II collagen and of
ﬁbronectin in their CAM (Table II). b-CDPS (5.0 mg/ml) in the
culture medium did not cause larger effects. The effect sizes
of these increases varied amongst the three donor
chondrocyte populations. Some illustrative ﬂow cytometer
patterns are given in Fig. 3.
THE IGF-1/IGFR1 AUTOCRINE PATHWAY AND IL-1RII
When compared with controls, b-CDPS did not induce
any changes in plasma membrane-bound IGFR1. Intracel-
lular IGF-1 levels also remained unchanged after exposure
to the polysulphated cyclodextrin. Likewise, plasma mem-
brane-bound decoy IL-1RII did not change under CDPS
treatment (Table II).
EFFECTS ON THE IL-1/IL-1RI AUTOCRINE PATHWAY
Membrane-bound IL-1RI did not change under CDPS
treatment. However, intracellular IL-1a and b levels were
found downregulated after exposure of the chondrocytes to
b- or g-CDPS (Table II). No signiﬁcant differences in IL-1
repression were observed under 2.5 and 5.0 mg/ml of the
cyclodextrins, which were the optimal concentrations
revealed in the 35S-incorporation experiments. Percentage
decreases of both IL-1 isoforms exposed a more pro-
nounced effect on IL-1a. The effect sizes of this inhibition
also varied amongst the three donor chondrocyte popula-
tions and ranged in between 14.6% and 48.1%, and 6.0%
and 22.9% of inhibition for intracellular IL-1a and -b,
respectively (Table II). The smallest change in IL-1 levels
concurred with the least increase in accumulated CAM
compounds.Fig. 3. Fluorescence intensity patterns of chondrocytes labelled with FITCemAb directed against intracellular IL-1a and -b, CAM aggrecan,
type II collagen and ﬁbronectin illustrate how small changes in IL-1 producing cells, induce vast increases in the accumulation of CAM
products. Isotype control curves and ﬂuorescence intensity patterns of 5.0 mg/ml of b-cyclodextrin (bCD)-treated and control cells are shown
for each of the tested variables. Donor: M18; Ordinate: events (number of cells) studied; abscissa: ﬂuorescence intensity.
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Chondrocytes from OA regions secreted 2e3 times more
IL-6 in the supernatant media than cells from intact
cartilage. TNFa (100 pg/ml) caused a fourfold increase in IL-6
release by normal chondrocytes in culture. b-cyclodextrin
polysulfate (5 mg/ml) depressed IL-6 release by normal and
OA chondrocytes to approximately 60% of the baseline
values. A 25% repression of the release of IL-6 by 5.0 mg/ml
b-cyclodextrin-treated TNFa-primed chondrocytes was ob-
served (Fig. 4).
Discussion
Catabolic cytokines, e.g., IL-1, affect the homeostasis of
the ECM in normal and OA cartilage and are produced by
chondrocytes themselves25,26. In OA chondrocytes or
cartilage, the upregulation of the catabolic IL-1a and b
pathways has been reported27,28 and a correlation with
the occurrence and the degree of OA pathology was noted
for IL-1b25,26,29. Increased IL-1 release by chondrocytes
has been reported to be mediated by TNFa30. Auto/
paracrine TNFa resulting from apoptosis of chondrocytes
following excessive mechanical stress31,32 may thus induce
an IL-1-induced destruction of the extracellular environment
of articular cartilage.
Agents that possibly alter the evolution of degenerative
joint disease (DMOAD) should at least demonstrate how farthey affect connective tissue metabolism in suitable in vitro
models. Human articular chondrocytes maintain their
original phenotype and metabolic characteristics when
cultured in alginate gel18,21,33e46. Articular cartilage cells
in this culture condition synthesise cartilage-speciﬁc colla-
gens and ECM aggrecans33,34. Recently, it has been shown
that chondrocytes obtained from intact tissues maintain
their normal metabolism, whereas chondrocytes from OA
cartilage retain their catabolic phenotype when cultured in
alginate37. The system is suitable for the study of the effects
of putative pharmaceutical agents on behaviour in vitro of
human chondrocytes.
In most in vitro conditions tested so far, 35SO4 used by
phenotypically stable cartilage cells is incorporated for the
most part in aggrecan. Variations in low hydrodynamic size
proteoglycans such as decorin, biglycan, ﬁbromodulin, type
XI collagen and other physiologically important but less
abundant extracellular macromolecules are not studied with
these approaches. Hence, the incorporation by chondro-
cytes of 35Sulphate in macromolecules is commonly
considered to be a variable reﬂecting aggrecan synthesis.
Increased 35S-incorporation would unlikely have resulted
from an increase in cell numbers or from an improved
sulphating of the aggrecan glycosaminoglycan chains
during exposure to the b-cyclodextrins. Polysulphated
polysaccharides were never shown to increase cell pro-
liferation. In addition, no reports exist on the degree of
sulphating of glycosaminoglycan chains produced byTable II
Effects of b-CDPS on the expression of growth factors, cytokines, their receptors and ECM components by chondrocytes in alginate
Control 2.5 mg/ml 5.0 mg/ml % Change
M18
IGFRI 12.5G 0.1 13.3G 0.6 13.6G 1.0
IGF-1 47.6G 0.3 48.5G 1.4 49.6G 0.4
IL-1RI 14.0G 0.5 13.4G 1.4 15.1G 1.2
IL-1RII 13.2G 0.3 13.8G 0.6 14.2G 1.3
IL-1a 82.8G 1.5 67.7G 2.3*1 53.0G 0.6*2 36.0
IL-1b 86.7G 2.2 82.0G 3.4*1 81.5G 2.0*1 6.0
Aggrecan 37.6G 1.0 52.3G 1.8*2 66.4G 3.4*2 C76.6
Collagen II 21.7G 1.7 42.6G 2.2*2 42.6G 3.0*2 C96.3
Fibronectin 219.8G 18.0 325.6G 10.1*2 326.2G 15.8*2 C48.4
F55
IGFRI 12.9G 0.4 12.3G 0.2 12.8G 0.4
IGF-1 65.9G 2.3 63.7G 1.4 61.9G 2.0
IL-1RI 12.4G 0.3 12.0G 0.6 12.0G 0.5
IL-1RII 12.8G 0.4 13.2G 0.8 12.9G 0.2
IL-1a 29.5G 1.8 25.0G 0.6*1 25.2G 1.0*1 14.6
IL-1b 24.7G 1.7 21.7G 1.0*1 21.4G 1.0*1 13.4
Aggrecan 21.1G 1.1 24.5G 0.8*2 26.3G 0.3*2 C24.6
Collagen II 22.0G 2.1 29.0G 1.7*1 27.4G 2.1*1 C24.5
Fibronectin 387.1G 8.4 411.4G 8.2*1 434.4G 16.8*1 C12.2
F68
IGFRI 12.4G 0.8 12.1G 0.2 12.4G 1.0
IGF-1 35.9G 0.9 36.7G 1.2 39.6G 3.6
IL-1RI 11.0G 1.0 11.8G 1.0 13.2G 0.6
IL-1RII 12.0G 0.3 11.7G 0.5 11.8G 0.5
IL-1a 46.8G 0.5 26.7G 0.8*3 24.3G 0.3*3 48.1
IL-1b 31.5G 0.8 25.2G 0.5*2 24.3G 0.3*2 22.9
Aggrecan 15.0G 0.7 19.4G 1.1*1 19.7G 0.2*2 C31.3
Collagen II 18.2G 1.0 22.5G 1.5*2 25.4G 0.9*2 C39.6
Fibronectin 98.4G 5.9 120.0G 8.3*1 163.4G 10.9*1 C66.1
Experiments done in triplicate. Mean MFI values of the cell populationG 1 SD are given. Donor: M/F-NR: male/female-age; *NR: signiﬁcance
levels: *1: P! 0.05; *2: P! 0.01; *3: P! 0.001; % change: percentage differences between values of control chondrocytes and chondrocytes
under 5.0 mg/ml of b-CDPS.
893Osteoarthritis and Cartilage Vol. 13, No. 10phenotypically stable cartilage cells in culture in alginate. It
is assumed that glycosaminoglycan sulphating in this
condition will not differ widely from sulphating values
reported in tissue explants. Undersulphated disaccharides
represent merely 5% of the disaccharides in glycosamino-
glycan chains in these explants38. A possible increase in
sulphating by b-cyclodextrin of the almost 95% sulphated
glycosaminoglycan disaccharides in this experimental
condition could not explain the 30e60% increases in 35S-
incorporation reported here.
35Sulphate incorporation in aggrecan was thus used as
a measure to ﬁnd out the optimal working concentration with
these polysulphated a-, b- and g-cyclodextrins. The alginate
is an unsulphated polysaccharide and differences in levels
of the added sulphated polysaccharides in media and the
artiﬁcial matrix did probably not occur. Cyclodextrin dose-
response curves showed optimal effects at 2.5e5.0 mg/ml of
the sulphated polysaccharides. Apparently, the three
polysulphated cyclodextrins did not differently affect 35S-
aggrecan synthesis. The increase in aggrecan synthesis
was obvious in the chondrocytes obtained from different
donors. Higher doses of the three cyclodextrins inhibited
35S-aggrecan synthesis. These bell-shaped dose-effect
curves have been previously reported when other over-
sulphated polysaccharides were used13,39,40. The inhibition
of aggrecan synthesis at higher concentrations of the
polysulphated polysaccharides in the incubation medium
was not due to direct toxic effects on the chondrocytes as
the cells did not stain with trypan blue when exposed to
pg/ml (1/100) IL-6
NO NO+TNF OA
control
0
50
100
150
200
250
300
350
400
-cyclodextrin
Fig. 4. IL-6 release by normal (NO), normal TNFa-primed
(NOC TNF), and OA chondrocytes. : control cultures, : b-
cyclodextrin-treated cells. Experiments were done in triplicate.
Mean valuesG 1 SD are shown.these high cyclodextrin concentrations (results not shown).
Unpublished observations in this laboratory showed this
inhibition to occur at even lower polysaccharide concen-
trations when low amounts of serum were supplemented to
the nutrient media of these chondrocyte cultures. Hence,
the lowered synthesis rates of ECM macromolecules could
be possibly explained by the tendency of these polysulph-
ated polysaccharides to bind to various biological agents of
protein nature. This quality has been exploited in various
polysaccharide polysulphate (e.g., heparin, dextransul-
phate)-loaded afﬁnity chromatography columns to remove
and to purify cytokines and growth factors from biological
ﬂuids41,42.
Polysulphated polysaccharides with different molecular
structures, e.g., heparin, chondroitin sulphate, (CPS) and
xylosan polysulphate, have been found to modulate
connective tissue metabolism. As the exposure of connec-
tive tissue cells in culture to these polysaccharides almost
invariably caused increased extracellular amounts of 35S-
proteoglycan and 3H-glucosamine-labelled hyaluronan, it
was assumed that these agents directly enhanced the
synthesis rates of these ECM macromolecules7,8,12,13. Our
present ﬁndings, however, reveal a new paradigm by which
increased synthesis rates of aggrecan could have resulted
from a repression of an autocrine chondrocyte IL-1 pathway
as IL-1 is known to decrease the synthesis of aggrecan via
nitric oxide (NO)43,44. Some of these polysulphated
saccharides have been shown to directly inhibit45e50, or to
slow down the production51,52 of a variety of enzymes that
are capable of digesting important ECM compounds. Our
ﬁnding that these polysulphated cyclodextrins decreased
IL-1a and -b levels inside the cells supports their
anticatabolic activities. These intracellular cytokines repre-
sent a reservoir of biologically active agents, of which
variable amounts are secreted as a result of various stimuli.
It can be anticipated that the intracellular amounts of these
bioactive molecules predict their extracellular function.
Obviously, the inhibition of these auto/paracrine catabolic
pathways was followed by a signiﬁcantly increased accu-
mulation of CAM aggrecan, type II collagen and ﬁbronectin.
The fact that b-CDPS interferes with chondrocyte IL-1
was further exempliﬁed by the effects on IL-6 release in the
incubation media. Considering the role of auto/paracrine IL-
1 pathways in the secretion of IL-6 by articular cartilage
cells53,54, we studied the release of IL-6 as an IL-1-
dependent variable by chondrocytes obtained from both
normal and OA cartilages. We found that OA cells secreted
signiﬁcantly more IL-6 than normal chondrocytes, illustrat-
ing the well-documented increase of auto/paracrine IL-1
activity in OA chondrocytes. b-CDPS inhibited the synthesis
of IL-6 in both normal and OA chondrocytes. Although the
experiments were not performed in the presence of IL-1-
blocking antibodies, it is supposed that b-cyclodextrin
affected the IL-1 loop and did not directly impede the
production of IL-6.
Furthermore, b-CDPS inhibited the release of IL-6 by
TNFa-primed chondrocytes. Although a possible down-
modulation of TNF effects by b-cyclodextrin was not
excluded in these experiments, we postulate that the
impaired IL-6 release could have been obtained through
an interference with IL-1.
It is as yet speculative to defend the use of oversulphated
cyclodextrins to protect cartilage in clinical conditions such
as OA. The effects, however, of these agents on articular
cartilage cell metabolism illustrate their ‘structure modifying
effects’ on connective tissues and may predict their
properties as DMOAD.
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